Circulating alpha-fetoprotein-specific T-cell responses are associated with clinical outcomes after radiofrequency ablation or immunotherapy in hepatocellular carcinoma
Background: Circulating tumor antigen–specific T-cell responses are promising peripheral immune biomarkers associated with treatment efficacy, yet clinical translation is hampered by incomplete epitope maps and non-standardized assays. This study aimed to map the T-cell epitope repertoire of AFP and develop a PBMC-based assay to quantify circulating AFP-specific T-cell responses in HCC. Methods: CD8 + T-cell epitopes in AFP were screened using in silico prediction, peptide-PBMC coculture, peptide competitive binding assays, and immunization in HLA-transgenic mice, and then applied in clinical cohorts. Results: Totally, 48 CD8 + T-cell epitopes identified here and 20 from our previous study were confirmed immunogenic. These peptides were used to establish an IFN-γ ELISpot assay for quantifying circulating AFP-specific T-cell responses in PBMCs. A total of 170 HCC patients with elevated serum AFP were included in two derivation cohorts: 80 patients treated with RFA and 90 receiving anti-PD-1 plus anti-VEGF therapy. In the RFA derivation cohort, the post-treatment/pre-treatment fold of AFP-specific T-cell responses was independently associated with DFS (AUC, 0.838; cutoff, 1.95-fold for DFS >12 vs. ≤12 mo). In the anti-PD-1 plus anti-VEGF derivation cohort, the post-treatment/pre-treatment fold of AFP-specific T-cell responses was independently associated with objective response and 6-month PFS (AUC, 0.850 and 0.863, respectively), with a unified 2.5-fold cutoff for outcome stratification. These findings in the immunotherapy setting were further validated in an independent external cohort of 50 HCC patients with elevated serum AFP receiving combined anti-PD-1 and anti-VEGF therapy. Conclusions: This study establishes an IFN-γ ELISpot assay for quantifying circulating AFP-specific T-cell responses in PBMCs and supports their potential translational utility as a novel peripheral immune-monitoring biomarker associated with clinical outcomes in AFP-positive HCC patients.
Authors
- Yi Wu (ORCID: https://orcid.org/0000-0003-1386-1304)
- Chuanlai Shen (ORCID: https://orcid.org/0000-0002-3748-3742)
- Fangping Yue
- Yandan Wu
- Qingwei Song (ORCID: https://orcid.org/0009-0004-9152-4092)
- Yu Zhao
- Dengyong Zhang
- Song Yang
- Wanliang Sun
- Suyue Zhu
- Shilong Song
Institutions
- Xuzhou Medical College (CN)
- Affiliated Hospital of Xuzhou Medical College (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- Southeast University (CN)
Publication Details
- Journal
- Hepatology Communications
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1097/hc9.0000000000001050
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00